Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Accumulated Expenses (2016 - 2025)

Avanos Medical's Accumulated Expenses history spans 11 years, with the latest figure at $82.7 million for Q3 2024.

  • For Q3 2024, Accumulated Expenses fell 14.92% year-over-year to $82.7 million; the TTM value through Sep 2024 reached $82.7 million, down 14.92%, while the annual FY2022 figure was $98.9 million, 45.23% up from the prior year.
  • Accumulated Expenses for Q3 2024 was $82.7 million at Avanos Medical, down from $97.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $98.9 million in Q4 2022 and bottomed at $68.1 million in Q4 2021.
  • The 5-year median for Accumulated Expenses is $83.0 million (2020), against an average of $84.7 million.
  • The largest annual shift saw Accumulated Expenses decreased 27.53% in 2020 before it skyrocketed 45.23% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $83.2 million in 2020, then decreased by 18.15% to $68.1 million in 2021, then surged by 45.23% to $98.9 million in 2022, then decreased by 1.72% to $97.2 million in 2023, then fell by 14.92% to $82.7 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Accumulated Expenses are $82.7 million (Q3 2024), $97.2 million (Q3 2023), and $98.9 million (Q4 2022).